Beth Israel Deaconess Medical Center

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Technology, Medical Devices, Professional Services, Cardiology, Software, Biometrics, Health, Data Analytics, Artificial Intelligence, Medical director, Interventional cardiology, Doctor of Philosophy, Cleveland, AI, International Society, Cleveland Clinic, Baylor Scott & White Medical Center – Temple, Beth Israel Deaconess Medical Center, Physician, American Heart Association, Digital health, Teaching, Electrophysiology, Patient, Ventricular tachycardia, Stanford University, Cardiac catheterization, Atrial fibrillation, Department of Medicine – University of Pamplona, Research, Development, Cornell University, Cordis, United States Air Force Scientific Advisory Board, Digital, Harvard Medical School, Innovation, White, Strategic planning, Stanford University School of Medicine, Arrhythmia, Johnson & Johnson, Weill Cornell Medicine, SAB, Associate, Management, Pharmaceutical industry, Medical device, Medicine, MD, Brigham

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Retrieved on: 
Tuesday, October 31, 2023
Week, FDA, Psoriasis, HS, Flare, Harvard Medical School, Secukinumab, Beth Israel Deaconess Medical Center, MPH, Abscess, Doctor of Education, US Food Sovereignty Alliance, Hidradenitis suppurativa, Inflammation, HIV disease progression rates, EAST, Skin, International Association, Novartis, Disease, Medicine, Physician, Scar, Anxiety, Pain, Patient, Diagnosis, SUNRISE, Rheumatology, Pharmaceutical industry, Dermatology, MD

"This approval marks an important milestone for countless patients who have been faced with limited treatment possibilities and who now have a new option."

Key Points: 
  • "This approval marks an important milestone for countless patients who have been faced with limited treatment possibilities and who now have a new option."
  • "HS is one of the most devastating and exhausting skin diseases.
  • The pain of flares can be debilitating and limits my ability to work or participate in social activities.
  • "The approval of a new treatment option brings fresh hope to me and the HS community that we may find relief from the burden of the disease."

Avertix Data Presented at TCT 2023 Shows 150% Increase in Medication Adjustments of Antiarrhythmics for High-Risk Heart Attack Survivors

Retrieved on: 
Tuesday, October 24, 2023
Patient, FDA, American College, Harvard Medical School, Splenic infarction, Beth Israel Deaconess Medical Center, History, Physician, Treatment, FACC, Cardiology, Acute coronary syndrome, Research, STEMI, Prescription, Risk, ACS, Coronary occlusion, FHRS, Safety, TCT, System, Vein, American College of Cardiology, Pharmaceutical industry, Medical device, Guardian, Electrophysiology

EATONTOWN, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), creator of the world’s first and only real-time heart attack detection and patient alerting system designed to improve long-term management and outcomes of recurrent events in high-risk patients who have survived one or more heart attacks, announced The Guardian System™ data was presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The study found an increase of more than 150% in new administration or titration of medications related to rate and rhythm abnormalities in patients whose Guardian™ alarms were activated compared to patients whose alarms were off.

Key Points: 
  • The Guardian System, the first and only FDA-approved implantable heart attack detection and warning system, also alerts patients in real-time of abnormal heart rates and rhythms and provides a recent history of intracardiac recordings.
  • “This data has provided us with valuable insights into addressing the care needs of high-risk Acute Coronary Syndrome (ACS) patients,” said Dr. Kaplan.
  • “With a career-long commitment to improving patient wellbeing and advancing cardiovascular research, The Guardian System is changing the paradigm for heart attack survivors,” said Dr. Gibson.
  • In addition to endpoints assessing ACS events, the trial collected data on medication usage and adjustments.

THE PROSTATE CANCER FOUNDATION AND BAYER ANNOUNCE FIRST EVER BAYER-PCF DAROLUTAMIDE CHALLENGE AWARDS

Retrieved on: 
Wednesday, October 25, 2023
FDA, Food, Beth Israel Deaconess Medical Center, Darolutamide, Prostate cancer, Docetaxel, Dana–Farber Cancer Institute, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Disease, Prostate Cancer Foundation, ARI, PCF, Cancer, Patient, Principal investigator, Pharmaceutical industry, Bayer, MD

LOS ANGELES, Oct. 25, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical investigations on darolutamide in prostate cancer.

Key Points: 
  • LOS ANGELES, Oct. 25, 2023 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Bayer today announced two 2023 Bayer-PCF Darolutamide Challenge Awards totaling $2 million to support clinical investigations on darolutamide in prostate cancer.
  • In 2019, the U.S. Food and Drug Administration approved Bayer's Nubeqa® (darolutamide), an androgen receptor inhibitor (ARI), for the treatment of adults with non-metastatic, castration-resistant prostate cancer (nmCRPC).
  • In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer (mHSPC), or metastatic prostate cancer patients receiving their first line of hormonal treatment.
  • The teams awarded 2023 Bayer-PCF Darolutamide Challenge Awards are:
    Co-Investigators: Heather Jacene, MD, Mary-Ellen Taplin, MD, Jacob Berchuck, MD, all of Dana-Farber Cancer Institute; Steve Balk, MD, Beth Israel Deaconess Medical Center

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Illinois College, MedImmune, NCI, Molecular biology, AstraZeneca, Beth Israel Deaconess Medical Center, Senior, Macrogen, Princeton University, University, Internal medicine, National Cancer Institute, Carcinoma, Beth, Patient, Human Genome Sciences, Nursing, Immunome, Seagen

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.

Key Points: 
  • Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer.
  • Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.
  • “We are delighted to welcome Bob to our team during an exciting time in Immunome’s growth as we focus on advancing our oncology pipeline into the clinic,” said Dr. Siegall, President and Chief Executive Officer of Immunome.
  • I would like to extend my thanks to Dr. Siegall and the entire Immunome team for welcoming me to the company,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.

Boston IVF Showcases Pioneering Fertility Research at the 2023 ASRM Scientific Congress & Expo

Retrieved on: 
Thursday, October 19, 2023
Embryology, Knowledge, Patient, Protocol, Research, Harvard Medical School, American Association of Clinical Endocrinologists, MPH, Beth Israel Deaconess Medical Center, Clinical research, Hope, RESEARCH, Congress, 2001 Slovenian fertility treatment referendum, Probability, Impact, MBA, Health, Episcopal conference, Society, Male, Reproductive medicine, IVF, Partnership, Abstract, Merck Serono, Cryopreservation, Comparison, American Society for Reproductive Medicine, ASRM, Expo, Diversity, IUI, Infertility, Nursing, Pharmaceutical industry, Mineral oil, Birth control, Fertility, MD, Doctor of Philosophy

BOSTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Boston IVF, a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo. This prestigious annual event, in New Orleans, Louisiana, from October 14-18, brought together global experts to share groundbreaking advancements in technology, treatments, and patient care in reproductive medicine.

Key Points: 
  • Charting a Path to Tomorrow, Boston IVF's Groundbreaking Research in 2023 Continues to Shape the Future of Fertility Care
    BOSTON, Oct. 19, 2023 /PRNewswire-PRWeb/ -- Boston IVF , a renowned leader in fertility research and patient care since its establishment in 1986, is proud to announce its substantial participation in the 2023 American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo .
  • – David Stern, CEO of Boston IVF
    Boston IVF's team of reproductive endocrinologists, scientists, clinicians, and researchers presented over 20 pioneering research studies, along with education symposia and roundtables.
  • This year, four distinguished individuals from Boston IVF were recognized nationally by the ASRM for their exceptional contributions:
    Yuval Fouks, MD, PhD, MPH a dedicated Research Fellow at Boston IVF, was honored with the ASRM 2023 IN TRAINING AWARD FOR RESEARCH for his noteworthy publication in Fertility and Sterility.
  • (Source: Fertility & Sterility)
    Quetrell Heyward, MD, MBA, a Reproductive Endocrinology and Infertility Fellow at Boston IVF & Beth Israel Deaconess Medical Center, received the prestigious ASRM 2023 INVESTIGATOR ACHIEVEMENT AWARD.

ProciseDx Expands Intellectual Property Portfolio with Purchase of Two US Therapeutic Drug Monitoring Patents

Retrieved on: 
Wednesday, October 18, 2023
Laboratory, FDA, C-reactive protein, Infliximab, Family, TNF, Doctor of Philosophy, Inflammatory bowel disease, Beth Israel Deaconess Medical Center, Antibody, Adalimumab, IBD, Patient, TDM, Therapeutic drug monitoring, CRP, SAN, Pharmaceutical industry, MD

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.
  • 11,119,096 "Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug antibodies in samples" and US Patent No.
  • "We believe these patents as well as our existing intellectual property forms a solid foundation for our path forward in expanding our reach in therapeutic drug monitoring of biological drugs," said Larry Mimms, PhD, CEO of ProciseDx.
  • ProciseDx received FDA clearance for the ProciseDx analyzer and first immunoassay for C-Reactive protein (CRP) in November, 2022.

ProShares Names Steve Vanourny as Head of Corporate Development, Strategy and Planning

Retrieved on: 
Monday, October 16, 2023
Banking, Professional Services, Finance, MBA, Beth Israel Deaconess Medical Center, Senior management, Dartmouth College, Partner, ETF, Harvard University, McKinsey & Company, Growth, State Street, ProShares, Corporate development, Harvard Business School, Management, Security (finance)

ProShares, a premier provider of ETFs, announced today that Steve Vanourny has joined the firm as Managing Director, Head of Corporate Development, Strategy and Planning.

Key Points: 
  • ProShares, a premier provider of ETFs, announced today that Steve Vanourny has joined the firm as Managing Director, Head of Corporate Development, Strategy and Planning.
  • In this newly created role, Mr. Vanourny is charged with a diverse set of responsibilities, including long-term and annual planning, new product development, business intelligence, and partnerships and acquisitions.
  • Mr. Vanourny will report directly to ProShares’ CEO Michael L. Sapir and serve on the firm’s Management Team.
  • Mr. Vanourny joins ProShares with nearly three decades of asset management experience, serving as Global Head of Strategy and Global Head of Investment Analytics at State Street, as well as a Partner in McKinsey & Co’s asset and wealth management practice.

Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances

Retrieved on: 
Friday, October 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Woman, Pain, Drainage, Beth Israel Deaconess Medical Center, Autoimmunity, Prevalence, Cell, MPH, Report of the 1st Annual Symposium on Relaxed Improvisation, Rheumatoid arthritis, CAR, Harvard Medical School, Protein, Black, Immune system, Scar, Hidradenitis suppurativa, Northwest Biotherapeutics, Skin, Inflammation, Patient, HS, Vaccine, Pharmaceutical industry, Regulatory T cell, Dermatology

Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg product candidate for the treatment of hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA).

Key Points: 
  • Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg product candidate for the treatment of hidradenitis suppurativa (HS) at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA).
  • “CAR-Treg therapies hold great promise for treating an array of autoimmune and inflammatory diseases,” said Mark D. Eisner, M.D., MPH, Chief Medical Officer of Sonoma Biotherapeutics.
  • “Our 7101 program targets citrullinated proteins, a hallmark of many autoimmune diseases, including rheumatoid arthritis and HS.
  • Our results show that we can engineer CAR Tregs directly from HS patients’ cells that can target these proteins.

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023
Memorial, Robert Wood Johnson Medical School, Doctor of Philosophy, Rutgers University, Internal medicine, Ipilimumab, Bristol Myers Squibb, Memorial Sloan Kettering Cancer Center, Therapy, Growth, Nivolumab, Harvard Medical School, Beth Israel Deaconess Medical Center, Fedratinib, Spacecraft, ADC, Broad arrow, Hematology, Patient, Pharmaceutical industry, MD

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company.
  • Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: "Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors.
  • He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.